论文部分内容阅读
对５６例初发急性髓系白血病（ＡＭＬ）细胞ＣＤ＿（３４）抗原的表达作了检测，分析了ＣＤ＿（３４）抗原表达与临床表现及化疗疗效的关系。结果显示，ＡＭＬ细胞的ＣＤ＿（３４）表达率存在很大差别，从１％～８５％；５６例ＡＭＬ中ＣＤ＿（３４）阳性表达病例为２３例，占４１．１％。ＣＤ＿（３４）抗原表达与ＦＡＢ形态学分型无关，但Ｍ＿３型的表达阳性率明显低于Ｍ＿１、Ｍ＿２型。ＣＤ＿（３４）￣＋病例组与ＣＤ＿（３４）￣－病例组在年龄、性别及初发时白细胞总数、血红蛋白浓度、血小板计数等均无明显差异；在诱导化疗疗效上，ＣＤ＿（３４）￣＋组完全缓解率为４３．５％，明显低于ＣＤ＿（３４）￣－组的７２．７％。研究结果提示，ＡＭＬ细胞在ＣＤ＿（３４）抗原的表达上存在异质性；并具有一定的预后判断价值，建议对ＣＤ＿（３４）￣＋病例施行更为有效的、可能需与ＣＤ＿（３４＿￣－病例不同的化疗。
The expression of CD_(34) antigen in 56 patients with acute myeloid leukemia (AML) was detected. The relationship between the expression of CD_(34) antigen and clinical manifestations as well as the efficacy of chemotherapy was analyzed. The results showed that the CD_(34) expression rate of AML cells varied greatly from 1% to 85%; in the 56 cases of AML, CD_(34) positive expression cases were 23 cases, accounting for 41.1%. The expression of CD_(34) antigen was not related to FAB morphological typing, but the positive rate of M_3 expression was significantly lower than that of M_1 and M_2. There was no significant difference in the total number of white blood cells, hemoglobin concentration, and platelet count between the CD34+ case group and the CD34+ case group at the age, sex, and initial stage; CD_(34)~ The complete remission rate in the + group was 43.5%, which was significantly lower than the 72.7% in the CD_(34)~-group. The results suggest that there is heterogeneity in the expression of CD_(34) antigen in AML cells and have a certain prognostic value. It is recommended that CD_(34)~+ cases be more effective and may require CD_(34_~ - Different chemotherapy cases.